biostudies-literatureWang JGuangdong Basic and Applied Basic Science FoundationNational Natural Science Foundation of ChinaSwedish Research Council supported by grants from the Swedish Research CouncilEuropean Union's Horizon Europe Research and Innovation ProgrammeNational Key Research and Development Program of ChinaShenzhen Bay LaboratoryChongqing Science and Technology Bureau and the Health CommissionSwedish State Support for Clinical Researche70038https://www.ebi.ac.uk/biostudies/studies/S-EPMC11953589biostudies-literatureUnknown21(3)<h4>Introduction</h4>This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD).<h4>Methods</h4>The diagnostic performance of the Lumipulse G plasma p-tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort (n = 391) and a community cohort (n = 121).<h4>Results</h4>Plasma p-tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p-tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p-tau217, Aβ42/Aβ40, p-tau181, and p-tau181/Aβ42 in both cAlzheimer's & dementia : the journal of the Alzheimer's AssociationDiagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.PMC119535892022-01018ALFGBG-7132081930028S241101004-12023YFC36054002019-02397821711972023-003562023B1515020113824220271010539622024GGXM003S241101004‐192249305Bourgeat PLai YJGuo TZhang LZetterberg HWang JDore VSun PTranslational Biomarker Research of AgIng and Neurodegeneration (TBRAIN)Bu XLChen YLiu YHLi AChen XTang YFripp JXiao ZSChen QMasters CLWang YJHuang SWang QHHe ZYu JTCai YLan GZeng FfalseDiagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.<h4>Introduction</h4>This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD).<h4>Methods</h4>The diagnostic performance of the Lumipulse G plasma p-tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort (n = 391) and a community cohort (n = 121).<h4>Results</h4>Plasma p-tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p-tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p-tau217, Aβ42/Aβ40, p-tau181, and p-tau181/Aβ42 in both c2025-01-01T00:00:00Z2025 Mar2025-07-11T03:04:11.38Z2025-07-11T03:04:11.38ZS-EPMC119535894015628610.1002/alz.70038